STUTTGART, Germany I July 21, 2025 I La Merie Publishing released its newest product entitled: TL1A Inhibitors & DR3 Antagonists: a Competitor Analysis ...

Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported ...

The pivotal Phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualized exacerbation rate (AER) at 52 weeks ...

EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic ...

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, ...

LEXINGTON, MA, USA I July 16, 2025 I Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New ...

We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis ...

The elritercept Phase 3 RENEW clinical trial (NCT06499285) is a global, randomized, double-blind, placebo-controlled trial in adults with transfusion-dependent anemia with very low, low, and ...

PITTSBURGH, PA, USA I July 18, 2025 I Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, ...

In connection with HekaBio’s recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial ...

The trial results demonstrated a favorable safety and tolerability profile consistent with GLP-1-based treatments and previously reported HRS9531 Phase 2 clinical data. Most treatment-emergent adverse ...

SEONGNAM, South Korea I July 17, 2025 I SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to ...